Risk of venous thromboembolism in patients undergoing cancer surgery and options for thromboprophylaxis

Journal of Surgical Oncology

Volumn 95, Issue 2, 2007, Pages 167-174

  Bergqvist, David ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Guidelines; Heparin; Malignancy; Prevention; Prophylaxis; Thrombosis

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THALIDOMIDE;

BLEEDING; CANCER SURGERY; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; IMMOBILIZATION; MULTIPLE MYELOMA; OSTEOPOROSIS; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD LOSS, SURGICAL; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; EVIDENCE-BASED MEDICINE; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES; PULMONARY EMBOLISM; RISK FACTORS; THROMBOEMBOLISM; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 33846897209     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20625     Document Type: Review

References (54)

1. Lee AY, Levine MN: Venous thromboembolism and cancer: Risks and outcomes. Circulation 2003;107:117-121.
2. Thodiyil PA, Walsh DC, Kakkar AK: Thromboprophylaxis in the cancer patient. Acta Haematol 2001;106:73-80.
3. Svendsen E, Karwinski B: Prevalence of pulmonary embolism at necropsy in patients with cancer. J Clin Pathol 1989;42:805-809.
4. Geerts WH, Pineo GF, Heit JA, et al.: Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:338S-400S.
5. Heit JA, Silverstein MD, Mohr DN, et al.: Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med 2000;160:809-815.
6. Baron JA, Gridley G, Weiderpass E, et al.: Venous thromboembolism and cancer. Lancet 1998;351:1077-1080.
7. Nordstrom M, Lindblad B, Anderson H, et al.: Deep venous thrombosis and occult malignancy: An epidemiological study. BMJ 1994;308:891-894.
8. Levitan N, Dowlati A, Remick SC, et al.: Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285-291.
9. Carson JL, Kelley MA, Duff A, et al.: The clinical course of pulmonary embolism. N Engl J Med 1992;326:1240-1245.
10. Monreal M, Kakkar AK, Caprini JA, et al.: The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Findings from the RIETE registry. J Thromb Haemost 2004;2:1892-1898.
11. Shen VS, Pollak EW: Fatal pulmonary embolism in cancer patients: Is heparin prophylaxis justified? South Med J 1980;73:841-843.
12. Prandoni P, Lensing AW, Cogo A, et al.: The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
13. Sorensen HT, Mellemkjaer L, Olsen JH, et al.: Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-1850.
14. Heit JA, O'Fallon WM, Petterson TM, et al.: Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: A population-based study. Arch Intern Med 2002;162:1245-1248.
15. Rickles FR, Levine MN: Epidemiology of thrombosis in cancer. Acta Haematol 2001;106:6-12.
16. Gallus AS: Prevention of post-operative deep leg vein thrombosis in patients with cancer. Thromb Haemost 1997;78:126-132.
17. Bergqvist D: Venous thromboembolism and cancer: Prevention of VTE. Thromb Res 2001;102:V209-V213.
18. Kakkar AK, Williamson RC: Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost 1999;25:239-243.
19. Stratton MA, Anderson FA, Bussey HI, et al.: Prevention of venous thromboembolism: Adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients. Arch Intern Med 2000;160:334-340.
20. Arnold DM, Kahn SR, Shrier I. Missed opportunities for prevention of venous thromboembolism: An evaluation of the use of thromboprophylaxis guidelines. Chest 2001;120:1964-1971.
21. Hull RD, Hirsh J, Carter CJ, et al. Diagnostic efficacy of impedance plethysmography for clinically suspected deep-vein thrombosis: A randomized trial. Ann Intern Med 1985;102:21-28.
22. Ibrahim EH, Iregui M, Prentice D, et al.: Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis. Crit Care Med 2002;30:771-774.
23. Anderson FA, Jr., Wheeler HB, Goldberg RJ, et al.: The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med 1992;152:1660-1664.
24. Wheeler HB: Diagnosis of deep vein thrombosis. Review of clinical evaluation and impedance plethysmography. Am J Surg 1985;150:7-13.
25. Clahsen PC, van de Velde CJ, Julien JP, et al.: Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol 1994;12:1266-1271.
26. Zangari M, Anaissie E, Barlogie B, et al.: Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001;98:1614-1615.
27. Bona RD: Central line thrombosis in patients with cancer. Curr Opin Pulm Med 2003;9:362-366.
28. Caine GJ, Stonelake PS, Lip GY, et al.: The hypercoagulable state of malignancy: Pathogenesis and current debate. Neoplasia 2002;4:465-473.
29. Sallah S, Wan JY, Nguyen NP: Venous thrombosis in patients with solid tumors: Determination of frequency and characteristics. Thromb Haemost 2002;87:575-579.
30. Thodiyil PA, Kakkar AK: Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost 2002;87:1076-1077.
31. Kakkar AK, Levine M, Pinedo HM, et al.: Venous thrombosis in cancer patients: Insights from the FRONTLINE survey. Oncologist 2003;8:381-388.
32. Guyatt G, Schunemann HJ, Cook D, et al.: Applying the grades of recommendation for antithrombotic and thrombolytic therapy: The Seventh ACCP Conference on Antithrombotic and Thrombolytic therapy. Chest 2004: 126:179S-187S.
33. Clagett GP, Reisch JS: Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 1988;208:227-240.
34. Hirsh J, Raschke R: Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:188S-203S.
35. Warkentin TE, Greinacher A: Heparin-induced thrombocytopenia: Recognition, treatment, and prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:311S-337S. Erratum in: Chest 2005;127:416.
36. Shaughnessy SG, Young E, Deschamps P, et al.: The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 1995;86:1368-1373.
37. Mismetti P, Laporte S, Darmon JY, et al.: Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001;88:913-930.
38. Maxwell GL, Myers ER, Clarke-Pearson DL. Cost-effectiveness of deep venous thrombosis prophylaxis in gynecologic oncology surgery. Obstet Gynecol 2000;95:206-214.
39. Dainty L, Maxwell GL, Clarke-Pearson DL, et al.: Cost-effectiveness of combination thromboembolism prophylaxis in gynecologic oncology surgery. Gynecol Oncol 2004;93: 366-373.
40. Mamdani MM, Weingarten CM, Stevenson JG: Thromboembolic prophylaxis in moderate risk patients undergoing elective abdominal surgery: Decision and cost-effectiveness analyses. Pharmacotherapy 1996;16:1111-1127.
41. Etchells E, McLeod RS, Geerts W, et al.: Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery. Arch Intern Med 1999;159:1221-1228.
42. Bergqvist D, Lindgren B, Mätzsch T: Comparison of the cost of preventing post-operative deep vein thrombosis with either unfractionated or low molecular weight heparin. Br J Surg 1996;83:1548-1552.
43. Heerey A, Suri S: Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery. Pharmacoeconomics 2005;23:927-944.
44. Bergqvist D, Burmark US, Flordal PA, et al.: Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg 1995;82:496-501.
45. Clark-Pearson DL, DeLong E, Syrian IS, et al.: A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obstet Gynecol 1990;75:684-689.
46. ENOXACAN Study Group: Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997;84:1099-1103.
47. Fricker JP, Vergnes Y, Schach R, et al.: Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest 1988;18:561-567.
48. McLeod RS, Geerts WH, Sniderman KW, et al.: Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: Results of the Canadian colorectal DVT prophylaxis trial: A randomized, double-blind trial. Ann Surg 2001;233:438-444.
49. Baykal C, Al A, Demirtas E, et al.: Comparison of enoxaparin and standard heparin in gynaecologic oncologic surgery: A randomised prospective double-blind clinical study. Eur J Gynaecol Oncol 2001;22:127-130.
50. Bergqvist D: Low molecular weight heparin for the prevention of venous thromboembolism after abdominal surgery. Br J Surg 2004;91:965-974.
51. Dahl OE, Aspelin T, Arnesen H, et al.: Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Thromb Res 1995;80:299-306.
52. Galster H, Kolb G, Kohsytorz A, et al.: The pre-, peri-, and postsurgical activation of coagulation and the thromboembolic risk for different risk groups. Thromb Res 2000;100:381-388.
53. Bergqvist D, Agnelli G, Cohen AT, et al.: Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975-980.
54. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, et al.: Prolonged prophylaxis with dalteparin to prevent late thromboemboic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemos 2006;4:2384-2390.